Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alemtuzumab (Campath 1-H).

Anna D Schaal1

  • 1DartmouthHitchcock Medical Center in Lebanon, NH, USA. anna.d.schaal@hitchcock.org

Clinical Journal of Oncology Nursing
|October 21, 2005
PubMed
Summary

Alemtuzumab is a targeted therapy for CD52-sensitive cancers. Subcutaneous administration offers effectiveness with fewer side effects, highlighting the role of nurses in patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot study of activity engagement in the first six months after stem cell transplantation.

Oncology nursing forum·2010
Same author

Building a collaboration of hematology-oncology advanced practice nurses. Part II: outcomes.

Oncology nursing forum·2008
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Alemtuzumab is a targeted therapy for CD52-positive malignancies.
  • It is utilized in various hematologic cancers with diverse dosing and administration routes.
  • The Cancer and Leukemia Group B is investigating alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) and acute lymphoblastic leukemia (ALL).

Purpose of the Study:

  • To explore the use of alemtuzumab in treating hematologic malignancies.
  • To evaluate different dosing schedules and routes of administration for alemtuzumab.
  • To assess the efficacy and safety of alemtuzumab, particularly the subcutaneous route, and the role of nurses in patient management.

Main Methods:

  • Clinical trials are investigating alemtuzumab in B-CLL consolidation and intensification therapy for ALL.
  • A national protocol is evaluating alemtuzumab in combination with fludarabine for relapsed/refractory B-CLL.
  • Studies are comparing subcutaneous (SQ) versus intravenous (IV) administration routes.

Main Results:

  • The subcutaneous route of alemtuzumab administration is gaining traction due to its effectiveness and reduced side effects compared to IV infusions.
  • Ongoing studies are assessing dose-escalation and combination therapies involving alemtuzumab.
  • Nurses play a crucial role in monitoring patient safety and tolerance.

Conclusions:

  • Alemtuzumab is a promising targeted therapy for CD52-sensitive hematologic malignancies.
  • The subcutaneous route offers a favorable safety profile.
  • Understanding alemtuzumab's mechanism and potential complications is vital for optimal nursing care and patient outcomes.

Related Experiment Videos